NCT02889393 - Teduglutide for Enterocutaneous Fistula (ECF) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

July 15, 2020

Study Completion Date

July 15, 2021

Conditions

Postoperative Fistula

Interventions

DRUG

Teduglutide

Daily 0.05 mg/kg Teduglutide administered subcutaneously.

OTHER

Standard of Care

The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.

Trial Locations (1)

33136

University of Miami, Miami